A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma

Description

The purpose of this study is to better understand why pancreatic cancer develops in some people who are known carriers of the gene mutation (an abnormality) called BRCA, or its close relative PALB2. The investigators hope to do this by establishing a BRCA/PALB2 mutation carriers Pancreatic Ductal Adenocarcinoma (the common form of pancreatic cancer) Registry. A registry is a database of information.

Conditions

Pancreatic Ductal Adenocarcinoma

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to better understand why pancreatic cancer develops in some people who are known carriers of the gene mutation (an abnormality) called BRCA, or its close relative PALB2. The investigators hope to do this by establishing a BRCA/PALB2 mutation carriers Pancreatic Ductal Adenocarcinoma (the common form of pancreatic cancer) Registry. A registry is a database of information.

A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma

A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma

Condition
Pancreatic Ductal Adenocarcinoma
Intervention / Treatment

-

Contacts and Locations

Basking Ridge

Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States, 07920

Middletown

Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States, 07748

Montvale

Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States, 07645

Cold Spring Harbor

Cold Springs Harbor Laboratory (Specimen Analysis), Cold Spring Harbor, New York, United States, 11724

Commack

Memorial Sloan Kettering Commack, Commack, New York, United States, 11725

Harrison

Memorial Sloan Kettering Westchester, Harrison, New York, United States, 10604

New York

Memorial Sloan Kettering Cancer Center, New York, New York, United States, 10065

New York

Weill Cornell Medical College (Specimen Analysis), New York, New York, United States,

Uniondale

Memorial Sloan Kettering Nassau, Uniondale, New York, United States, 11553

Philadelphia

Abramson Cancer Center at University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States, 19104-4283

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * BRCA mutation carrier is defined as a person with any mutation of the BRCA gene, including BRCA1, or BRCA2. PALB2mut patients are also eligible.
  • * Relative of a BRCA PDAC patient is defined as a first-degree relative, which includes, parents, siblings or children.
  • * Known BRCA mutation carrier.
  • * Ashkenazi Jewish Descent (at least one parent of Ashkenazi Jewish origin).
  • * Histologic proof of primary pancreatic ductal adenocarcinoma.
  • * May have either potentially curable (resectable) primary PDAC, localized but unresectable primary PDAC, or metastatic (stage IV) PDAC.
  • * Prior personal history of other malignancy; either prior or currently active, including breast , ovarian or prostate cancer is allowed.
  • * Both previously treated and previously untreated patients are eligible. Previous treatment may include surgical resection, regional radiation therapy, or systemic therapy. Patient may be receiving active therapy.
  • * Willing to provide blood specimens for correlative studies.
  • * Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material). New tumor biopsies are not required for entrance into the Registry.
  • * Know n BRCA mutation carrier.
  • * Histologic proof of primary pancreatic ductal adenocarcinoma.
  • * May have either potentially curable (resectable) primary PDAC, localized but unresectable primary PDAC, or metastatic (stage IV) PDAC.
  • * Prior personal history of other malignancy; either prior or currently active, including breast, ovarian, or prostate cancer is allowed.
  • * Both previously treated and previously untreated patients are eligible. Previous treatment may include surgical resection, regional radiation therapy, or systemic therapy. Patient may be receiving active therapy.
  • * Willing to provide blood specimens for correlative studies.
  • * Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material). New tumor biopsies are not required for entrance into the Registry.
  • * Known BRCA mutation carrier.
  • * Ashkenazi Jewish Descent (at least one parent of Ashkenazi Jewish origin).
  • * No current or prior history of PDAC.
  • * Relative of a BRCAmut PDAC patient; no prior or active personal history of breast, ovarian, or prostate cancer
  • * Willing to provide blood specimens for correlative studies.
  • * Know n BRCA mutation carrier.
  • * No current or prior history of PDAC.
  • * First or second degree relative of a BRCAmut PDAC patient; no prior or active personal history of breast, ovarian, or prostate cancer.
  • * Willing to provide blood specimens for correlative studies.
  • * Known BRCA mutation carrier.
  • * Ashkenazi Jewish Descent (at least one parent of Ashkenazi Jewish origin).
  • * No current or prior history of PDAC.
  • * Relative of a BRCAmut PDAC patient.
  • * Prior or active personal history of any BRCA-related cancer.
  • * Willing to provide blood specimens for correlative studies.
  • * Know n BRCA mutation carrier.
  • * No current or prior history of PDAC.
  • * First or second degree relative of a BRCAmut PDAC patient.
  • * Prior or active personal history of any BRCA-related cancer.
  • * Willing to provide blood specimens for correlative studies.
  • * Known BRCAmut carrier.
  • * Ashkenazi Jewish decent (at least one parent of Ashkenazi Jewish origin).
  • * No current or prior personal history of PDAC.
  • * Prior personal history of other malignancy including breast, ovarian or prostate cancer is allowed.
  • * Willing to provide blood specimens for correlative studies.
  • * Know n BRCAmut carrier.
  • * No current or prior personal history of PDAC.
  • * Prior personal history of other malignancy including breast, ovarian, or prostate cancer is allowed.
  • * Willing to provide blood specimens for correlative studies.
  • * Ashkenazi Jewish Descent (at least one parent of Ashkenazi Jewish origin).
  • * Not related to known BRCAmut carrier.
  • * Histologic proof of primary pancreatic ductal adenocarcinoma. May have either potentially curable (resectable) primary PDAC, localized but unresectable primary PDAC, or metastatic (stage IV) PDAC.
  • * Both previously treated and previously untreated patients are eligible. Previous treatment may include surgical resection, regional radiation therapy, or systemic therapy. Patient may be receiving active therapy.
  • * Willing to provide blood specimens for correlative studies.
  • * Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material). New tumor biopsies are not required for entrance into the Registry
  • * Individuals will be excluded from the Registry if they:
  • * Are unable to sign informed consent for medical or other reasons. Do not speak English (MSK and UPenn) or do not speak English or Hebrew (BCGC Sites).
  • * Are under 21 years of age.
  • * Not willing to provide blood samples for correlative studies.

Ages Eligible for Study

21 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Memorial Sloan Kettering Cancer Center,

David Kelsen, MD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

2025-11